Treatment of pulmonary metastases from kidney cell carcinoma with inhalational interleukin-2. 10-year experience Hamburger Unicenter

[1]  H. Heinzer,et al.  Subjective and objective prospective, long-term analysis of quality of life during inhaled interleukin-2 immunotherapy. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  H. Heinzer,et al.  A COMPARISON OF 2 MODES OF ADMINISTRATION OF RECOMBINANT INTERLEUKIN 2: INHALATIVE VERSUS SYSTEMIC THERAPY , 1999 .

[3]  D. Krebs,et al.  Additive Immuntherapie bei pulmonal metastasierten gynäkologischen Karzinomen mit inhalativem Interleukin-2-Ergebnisse der Feasibility Studie , 1999 .

[4]  H. Heinzer,et al.  Inhaled interleukin-2 therapy in pulmonary metastatic renal cell carcinoma: six years of experience. , 1997, The cancer journal from Scientific American.

[5]  A. Enk,et al.  Therapie von Lungenmetastasen des malignen Melanoms mit inhalativem IL-2 , 1997, Der Hautarzt.

[6]  C. Peschel,et al.  Phase I trial of inhaled natural interleukin 2 for treatment of pulmonary malignancy: toxicity, pharmacokinetics, and biological effects. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  Thomas J. Smith,et al.  Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. American Society of Clinical Oncology. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  S. Rosenberg,et al.  Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. , 1994, JAMA.

[9]  R. Figlin,et al.  Concomitant administration of recombinant human interleukin-2 and recombinant interferon alfa-2A: an active outpatient regimen in metastatic renal cell carcinoma. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  M. Goepel,et al.  Adjuvant therapy in renal cancer , 1991, World Journal of Urology.

[11]  H. Kirchner,et al.  Home therapy with recombinant interleukin-2 and interferon-α2b in advanced human malignancies , 1990, The Lancet.

[12]  H. Huland,et al.  Local continuous high dose interleukin 2: a new therapeutic model for the treatment of advanced bladder carcinoma. , 1989, Cancer research.

[13]  W. Linehan,et al.  Experience with the Use of High‐Dose Interleukin‐2 in the Treatment of 652 Cancer Patients , 1989, Annals of surgery.

[14]  D. Trump,et al.  Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. , 1988, Cancer research.

[15]  W. M. Linehan,et al.  A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. , 1987, The New England journal of medicine.

[16]  G. Marshall,et al.  Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. , 1987, The New England journal of medicine.

[17]  S. Rosenberg,et al.  Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2. , 1986, Journal of immunology.

[18]  J. Dekernion,et al.  Treatment of advanced renal cell carcinoma--traditional methods and innovative approaches. , 1983, The Journal of urology.

[19]  H. Huland,et al.  In vivo system to detect long-term continuous release of bioactive interleukin-2 by immunopharmacological depot preparations in nude mice with human tumors , 2005, Journal of Cancer Research and Clinical Oncology.

[20]  H. Heinzer,et al.  Inhaled interleukin-2 in combination with low-dose systemic interleukin-2 and interferon α in patients with pulmonary metastatic renal-cell carcinoma: effectiveness and toxicity of mainly local treatment , 2005, Journal of Cancer Research and Clinical Oncology.

[21]  T. Nakamoto,et al.  Inhalation of interleukin-2 combined with subcutaneous administration of interferon for the treatment of pulmonary metastases from renal cell carcinoma. , 1997, International journal of urology : official journal of the Japanese Urological Association.

[22]  E. Lopez Hänninen,et al.  Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients. , 1996, The Journal of urology.